Krilogy Financial’s Clovis Oncology, Inc. CLVS Stock Holding History

Krilogy Financial’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-300	Closed	-$13K	–	793
2017 Q1	$13K	Hold	300	–	–	﹤0.01%	490
2016 Q4	$13K	Hold	300	–	–	﹤0.01%	490
2016 Q3	$11K	Hold	300	–	–	﹤0.01%	520
2016 Q2	$4K	Hold	300	–	–	﹤0.01%	637
2016 Q1	$6K	Hold	300	–	–	﹤0.01%	527
2015 Q4	$11K	Hold	300	–	–	0.01%	253
2015 Q3	$28K	Buy	+300	New	+$26K	0.01%	269

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Krilogy Financial's CLVS Position: Q2 2017 in Review

Krilogy Financial sold out of Clovis Oncology, Inc. (CLVS) in Q2 2017, closing a stake of 300 shares — an estimated $13K sold.

Krilogy Financial first reported a position in CLVS in Q3 2015 and held it in 7 quarters. The position peaked at $28K in Q3 2015. 271 funds tracked by Wall St. Rank hold CLVS as of Q2 2017.

Krilogy Financial reported no remaining Clovis Oncology, Inc. position as of Q2 2017 after selling out during the quarter.
Krilogy Financial sold 300 Clovis Oncology, Inc. shares in Q2 2017, an estimated $13K.
Krilogy Financial first reported a position in Clovis Oncology, Inc. in Q3 2015 and held it in 7 quarters.
Krilogy Financial's Clovis Oncology, Inc. position peaked at $28K in Q3 2015.
271 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2017.

Based on Krilogy Financial's 13F filing for Q2 2017, filed 15 Aug 2017.